Table 2.
Univariate and multivariate analyses for predictive factors of completion of six cycles of radium-223 treatment
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p value | OR | 95% CI | p value | |||
| Lower | Upper | Lower | Upper | |||||
| Concomitant use of ARTA (yes vs. no) | 0.262 | 0.099 | 0.694 | 0.007 | 0.338 | 0.112 | 1.015 | 0.053 |
| Median baseline ALP levels (> 328 IU/L vs. ≤ 328 IU/L) | 4.057 | 1.777 | 9.264 | 0.001 | 3.225 | 1.117 | 9.311 | 0.030 |
| Median baseline Hb levels (> 12.3 g/dL vs. ≤ 12.3 g/dL) | 5.889 | 2.469 | 14.044 | < 0.001 | 7.156 | 2.407 | 21.274 | < 0.001 |
| Median baseline LDH levels (> 285 IU/L vs ≤ 285 IU/L) | 1.533 | 0.712 | 3.297 | 0.275 | 1.121 | 0.398 | 3.161 | 0.829 |
| Median baseline PSA levels (> 35.9 ng/mL vs ≤ 35.9 ng/mL) | 3.243 | 1.445 | 7.279 | 0.004 | 2.604 | 0.939 | 7.219 | 0.066 |
| Concomitant use of BMA (yes vs. no) | 0.893 | 0.405 | 1.966 | 0.778 | 0.355 | 0.115 | 1.098 | 0.072 |
| Baseline pain (yes vs. no) | 2.677 | 1.225 | 5.848 | 0.014 | 3.004 | 1.112 | 8.116 | 0.030 |
| Previous use of docetaxel (yes vs. no) | 1.296 | 0.587 | 2.862 | 0.521 | 0.520 | 0.175 | 1.546 | 0.240 |
ARTA androgen receptor-targeted agent, ALP alkaline phosphatase, Hb hemoglobin, LDH lactate dehydrogenase, PSA prostate-specific antigen, BMA bone-modifying agent, OR odds ratio, CI confidence interval